Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Phathom Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 84 | 1 | 83 | 0 |
| Shares | 25.5M | 9 | 28.6M | +3.03M (+11.9%) |
| Value | $819.8M | $0 | $562.0M | −$257.9M (−31.5%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Avidity Partners Management LP | 1,896,000 | $37.3M | 0.79% |
| 683 Capital Management, LLC | 290,595 | $5.72M | 0.27% |
| Artal Group S.A. | 200,000 | $3.93M | 0.12% |
| Parkman Healthcare Partners LLC | 77,481 | $1.52M | 0.34% |
| Laurion Capital Management LP | 50,000 | $984.0K | 0.02% |
| Marshall Wace, LLP | 32,165 | $632.0K | 0.00% |
| Hennion & Walsh Asset Management, Inc. | 30,894 | $608.0K | 0.03% |
| Pictet Asset Management SA | 16,197 | $319.0K | 0.00% |
| Wells Fargo & Company | 8,793 | $173.0K | 0.00% |
| Denali Advisors LLC | 2,500 | $49.0K | 0.02% |
| UBS Group AG | 1,329 | $26.0K | 0.00% |
| Aquatic Capital Management LLC | 700 | $14.0K | 0.03% |
| Amplius Wealth Advisors, LLC | 660 | $12.0K | 0.00% |
| Huntington National Bank | 125 | $2.00K | 0.00% |
| HM Payson & Co | 111 | $2.00K | 0.00% |
| Daiwa Securities Group Inc. | 92 | $2.00K | 0.00% |
| Quadrant Capital Group LLC | 49 | $1.00K | 0.00% |
| Parallel Advisors, LLC | 72 | $1.00K | 0.00% |
Sold out (18)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Great Point Partners LLC | 220,863 | $7.09M |
| FMR LLC | 154,200 | $4.95M |
| WCM Investment Management, LLC | 104,380 | $3.35M |
| Penn Mutual Asset Management, LLC | 86,940 | $2.79M |
| Adage Capital Partners GP, L.L.C. | 81,600 | $2.62M |
| Woodline Partners LP | 29,903 | $960.0K |
| Martingale Asset Management L P | 19,908 | $640.0K |
| Boothbay Fund Management, LLC | 14,921 | $479.0K |
| Parametric Portfolio Associates LLC | 13,640 | $438.0K |
| Occidental Asset Management, LLC | 12,872 | $413.0K |
| Credit Suisse AG | 8,429 | $271.0K |
| SG Americas Securities, LLC | 8,420 | $270.0K |
| Voya Investment Management LLC | 7,968 | $256.0K |
| UBS Asset Management Americas Inc | 7,514 | $241.2K |
| STRS Ohio | 4,100 | $131.0K |
| Simplex Trading, LLC | 132 | $4.00K |
| Evolution Wealth Advisors, LLC | 114 | $4.00K |
| O'Shaughnessy Asset Management, LLC | 14 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Phathom Pharmaceuticals, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Berman Capital Advisors, LLC | 9 | $0 |